NF1 and neurofibromatosis type 1: To determine how CQ compares to the only drug currently approved by the FDA for the treatment of NF1 tumors, selumetinib, we compared the effects of each drug on NF1‐deficient cell viability using three human cell lines, each with a paired isogenic or patient‐matched control.